AI-generated · cited to primary sources · not investment advice · How we research
Biocon
Our verdict on Biocon isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company confirmed the successful launch of bBevacizumab during the quarter. (1 met, 1 exceeded across 2 tracked commitments)
“Generics: Early investments in GLP-1s and peptide APIs are gaining traction; upcoming launches to fuel double-digit growth for the full year”
R&D spending for the Biosimilars segment was optimized to 6% of revenue for the full year, which is below the guided range of 7-9%, indicating better cost control. (1 exceeded, 4 met across 5 tracked commitments)
“We've said, Tushar, that we would be in that 7% to 9% of revenues for R&D, and we continue to be in that range even now and on a full year basis, you will see us in that 7% to 9% range.”
See the full cited Management analysis of Biocon
How durable is the business?
The segment is accelerating, driven by new launches like Yesintek (Ustekinumab) and strong market share in oncology. Revenue grew 18% YoY, and EBITDA margins improved significantly due to operating leverage. (5 expanding across 2 engines)
“Biosimilars 2,756 ... YoY% (Adj)* 12 ... % Margin 23”
Biocon is expanding its physical footprint in the US to ensure supply chain resilience and direct market access, moving beyond just offshore manufacturing. (5 expanding)
“In the past, we have said North America is about 40%, Europe and a little bit of Japan, ANZ 35% and emerging market 25%.”
See the full cited Business Model analysis of Biocon
Where does growth come from?
The Biosimilars segment is showing accelerating growth momentum, with revenue increasing 18% YoY this quarter compared to the 12% previously noted, and EBITDA growing 36% on a like-for-like basis. (4 accelerating, 1 new trend across 5 signals, 2 leading indicators)
“Segment Revenue 2,756 ... YoY% 12 ... 4Q Revenues up 12% YoY, led primarily by North America market”
The insulin franchise is poised for a new wave of growth following the U.S. FDA approval of Kirsty (Insulin Aspart), the first and only interchangeable rapid-acting insulin in the U.S. (5 accelerating across 5 signals, 1 leading indicator)
“And we're looking to expand that to the commercial play in the second half of this fiscal year '27. So, watch this space, we will keep you posted on how Aspart ramps up”
See the full cited Future Growth analysis of Biocon
What could break the thesis?
While older oncology biosimilars (Ogivri, Fulphila) are maintaining strong market shares of 27%, management notes that pricing in the Adalimumab (Humira) market is 'softening' and settling at lower levels. (1 intensifying, 3 stable)
“But yes, I think we should budget for some erosion, Vishal. But tough to tell you one specific number because it will vary depending upon the product life cycle.”
R&D intensity is easing as a percentage of revenue, dropping from 14% in FY23 to 7% in H1 FY26, driven by the stage of development of current assets. (1 easing, 4 stable)
“R&D (Net) 277 [Cr] ... % of Revenue (Ex. Syngene) 8”
See the full cited Risk analysis of Biocon
Read the full thesis on Biocon
Biocon's Strategic Entry into the Global GLP-1 Market: A Deep Dive into Vertically Integrated Weight Loss Solutions
18 May 2026Biocon and the GLP-1 Opportunity: Scaling Manufacturing for the Global Weight Loss Market
17 May 2026Biocon and the GLP-1 Opportunity: Scaling Manufacturing for the Global Weight Loss Market
11 May 2026AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.